Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

1.7K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.7K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

1.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.7K
Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IFITM3 promotes an M2-like tumor-supportive microenvironment in acute myeloid leukemia.

Medical oncology (Northwood, London, England)·2026
Same author

Disseminated rhino-orbital-cerebral mucormycosis in Philadelphia chromosome-positive mixed phenotype acute leukemia: a case report and literature review.

Frontiers in medicine·2025
Same author

Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.

Hematology (Amsterdam, Netherlands)·2023
Same author

De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230

Hematology (Amsterdam, Netherlands)·2023
Same author

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Heliyon·2023
Same author

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.

Cancer management and research·2023

Related Experiment Video

Updated: Jul 30, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

685

Correlation between lymphoma and second primary malignant tumor.

Lingjuan Liu1, Qun Zhang2, Baoan Chen1

  • 1Department of Hematology and Oncology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, China.

Medicine
|May 12, 2023
PubMed
Summary

Lymphoma patients face increased risks of secondary primary malignancies (SPMs), with varying risks based on patient characteristics and treatment. SPMs significantly lower survival rates compared to primary tumors, necessitating tailored follow-up plans.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Related Experiment Videos

Last Updated: Jul 30, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

685
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Area of Science:

  • Oncology
  • Epidemiology
  • Cancer Research

Background:

  • Limited research exists on secondary primary malignancies (SPMs) in lymphoma survivors, particularly regarding risk factors and comparative survival.
  • Understanding SPM development is crucial for improving long-term outcomes in lymphoma patients.

Purpose of the Study:

  • To evaluate the cumulative incidence and risk factors of SPMs in lymphoma patients.
  • To compare the survival rates of SPMs versus matched primary malignant tumors.

Main Methods:

  • Retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) database (2000-2019).
  • Analysis included Fine-Gray competing risk regression for cumulative incidence, Poisson regression for risk factors, and Kaplan-Meier analysis for survival.
  • Propensity score matching was used for survival comparisons.

Main Results:

  • The cumulative incidence of SPMs over 20 years was 1.95% (respiratory), 0.14% (CNS), 0.82% (hepatobiliary), 1.31% (urinary), and 1.92% (digestive).
  • Lymphoma patient characteristics, radiotherapy, chemotherapy, diagnosis time, age, and incubation period influenced SPM risk.
  • Secondary SPMs had significantly lower survival rates than matched primary malignant tumors.

Conclusions:

  • Lymphoma patients have a notable risk of developing SPMs, influenced by various factors.
  • Early consideration of SPM risk and personalized follow-up strategies are essential for lymphoma survivors.
  • Improved surveillance can mitigate the impact of SPMs and enhance patient survival outcomes.